Long-Term Follow Up of VOY-101 Non-nAMD Extension Study (OASIS)

June 16, 2026 updated by: Perceive Biotherapeutics, Inc.

Long-Term Follow Up of VOY-101 for Advanced Non-Neovascular Age-Related Macular Degeneration Extension Study

Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

This is a long-term observational, non-interventional extension study to the Phase 1/2a studies that administered VOY-101 to subjects with advanced non-neovascular age-related macular degeneration (AMD).

Study Type

Observational

Enrollment (Estimated)

88

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Israel
      • Tel Aviv, Israel, 6423906
        • Sourasky Medical Center - Ichilov
  • United States
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Ophthalmic Consultants of Boston
    • Texas
      • Bellaire, Texas, United States, 77401
        • Retina Consultants of Texas
    • Utah
      • Salt Lake City, Utah, United States, 84132
        • University of Utah

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101

Description

Inclusion Criteria:

  1. Have received an injection of VOY-101 and exited either the PBI-AMD-001 or PBI-AMD-002 Phase 1/2a study of VOY-101.
  2. Are willing and able to understand and provide informed consent.

Exclusion Criteria:

There are no exclusion criteria for this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101
Long-term safety extension from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101
Other: observational study
No intervention - observational study
Biological: VOY-101
One-time intravitreal injection of VOY-101.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of ocular and systemic VOY-101 related AEs
Time Frame: 3 years
Frequency of ocular and systemic VOY-101 related AEs (serious [SAEs] and treatment-emergent non-serious adverse events [TEAEs]).
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Perceive Biotherapeutics, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 3, 2026

Primary Completion (Estimated)

July 30, 2031

Study Completion (Estimated)

August 30, 2031

Study Registration Dates

First Submitted

June 16, 2026

First Submitted That Met QC Criteria

June 16, 2026

First Posted (Actual)

June 22, 2026

Study Record Updates

Last Update Posted (Actual)

June 22, 2026

Last Update Submitted That Met QC Criteria

June 16, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PBI-AMD-901

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Age-Related Macular Degeneration (AMD)

Clinical Trials on observational study

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe